disease-modifying antirheumatic drug
Factors associated with the achievement of biological disease modifying antirheumatic drug free remission in rheumatoid arthritis: the ANSWER cohort study
... Rheumatic Disease Patients; bDMARD: Biological disease-modifying antirheumatic drug; BFR: bDMARD-free remission; CCP: Cyclic citrullinated peptide; CI: Confidence interval; csDMARD: ...
10
<p>Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis</p>
... biological disease-modifying antirheumatic drug; CHEERS, the Consolidated Health Economic Evaluation Reporting Standards; CI, con fi dence intervals; combi, combi- nation therapy; csDMARD, ...
10
Early combination disease modifying antirheumatic drug therapy and tight disease control improve long term radiologic outcome in patients with early rheumatoid arthritis: the 11 year results of the Finnish Rheumatoid Arthritis Combination Therapy trial
... low disease activity at 11 years had received sig- nificantly shorter periods of combination DMARDs between 2 and 11 years than had the patients who had high disease activity at 11 years ...severe ...
8
Patient reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease modifying antirheumatic drug treatment
... synthetic disease-modifying anti-rheumatic drugs; DAS: Disease Activity Score; EQ-5D: EuroQol-5 Dimensions; EULAR: European League Against Rheumatism; FACIT-F: Functional Assessment of Chronic ...
10
Determining a low disease activity threshold for decision to maintain disease modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
... of disease activity in this range; namely, the ESR level, the patient's global activity, the number of tender joints and the number of swollen joints are taken into consideration by experts to make their ...
8
Comparative evaluation of the effects of treatment with tocilizumab and TNF α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients
... their disease duration was longer than six ...one disease- modifying antirheumatic drug (DMARD) or immu- nosuppressant were recommended for treatment with tocilizumab or TNF-α ...
10
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
... DAS28: Disease Activity Score modified to include the 28 diarthroidal joint count; DMARD: Disease- modifying antirheumatic drug; DSM-IV: American Psychiatric Association ’ s Diagnostic ...
12
Upadacitinib improves patient reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease modifying antirheumatic drugs: results from SELECT NEXT
... Biologic disease-modifying antirheumatic drug; BP: Bodily pain; CI: Confidence interval; csDMARD: Conventional synthetic disease-modifying antirheumatic drug; CCP: ...
11
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus
... infectious disease as the underlying conditions and immunomodulatory therapies weaken their immune response ...or disease-modifying antirheumatic drug (DMARD) treatment or both ...
9
Peroxisome proliferator activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial
... This trial was a single-center, randomized, double-blind, placebo-controlled crossover study with washout. We chose to use a crossover study design because this model increases the power to detect a difference with small ...
9
Effects of tofacitinib monotherapy on patient reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
... biologic disease-modifying antirheumatic drug; BP: bodily pain; cDMARD: non-biologic DMARD; BID: twice daily; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue; GH: General ...
12
Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial
... DAS28: Disease Activity Score 28; DMARD: Disease-modifying antirheumatic drug; DRKS: German Clinical Trials Register; DSMB: Data and safety monitoring board; DXA: Dual-Energy X-ray ...
7
Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
... DMArD, disease-modifying antirheumatic drug; esr, erythrocyte sedimentation rate; crP, c-reactive protein; DAs28, 28-joint Disease Activity score; hAQ, health assessment questionnaire; ...
8
Neuropathic like pain features and cross sectional associations in rheumatoid arthritis
... 28-joint Disease Activity Score; DMARD: Disease-modifying antirheumatic drug; DREAM: Dutch Rheumatoid Arthritis Monitoring; ESR: Erythrocyte sedimentation rate; FM: Fibromyalgia; FSQ: ...
8
No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta analysis
... a disease-modifying drug should be started as soon as rheumatoid arthritis (RA) is diagnosed with the objective of obtaining remission or at least a low level of ...synthetic ...
7
A phase III, randomized, two armed, double blind, parallel, active controlled, and non inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
... Adverse drug reaction; AS: Ankylosing spondylitis; BDMARDs: Biological disease-modifying antirheumatic drugs; CD: Crohn ’ s disease; CHF: Chronic heart failure; CHO: Chinese hamster ...
9
Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta analyses
... investigational drug barici- tinib 2 mg daily (qd) and 4 mg qd combined with meth- otrexate/csDMARD were included as this agent was at advanced regulatory stages at the time of ...
13
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study
... the drug and less frequent visits in ReAlise, and generally aligns with data from ADA clinical trials and registries ...the drug, the other possible explanations for the decrease in infection risk with ...
11
Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
... s disease (AOSD) and systemic onset ju- venile idiopathic arthritis (sJIA) are both considered to be multifactorial autoinflammatory diseases with a pre- dominant activation of the innate immune system [1 – ...
11
Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?
... established disease) the fifth MTPJs may have particular value as sensitive mar- kers of inflammatory arthritis [13,25], but these joints were not included in our routine screening ...
10